Thanks for posting the response. “What I’m
Post# of 147875
“What I’m saying is the lab data with the secondary endpoints chosen would clearly indicate to the expert eye who received LL and who didn’t.”
Bottom Line: Even if CYDY has seen the blinded bilirubin and platelet data, there’s no known correlation between decreased bilirubin/increased platelet levels and increased survivability rate in the COVID S/C population. No expert could simply say leronlimab is working of these two labs. If this were true, MM and the rest of CYDY would be buying shares non-stop.